Asian Institute Of Gastroenterology India
Hyderabad, Andhra Pradesh, 500082, India
NCT Number: NCT01321203
To assess the safety and efficacy of CO2 insufflations during ERCP
1. Primary objective:
To assess the patient's symptoms, abdominal pain and abdominal distension post procedure (ERCP) in the study group. 2. Secondary objective:
Endoscopist:
* To assess the adequacy of bowel distension for adequate luminal visualization * To assess the peristaltic movement during the ERCP
Anesthetist:
* To measure the PCO2 level in patient post procedure. * To assess the amount of sedation required during the procedure. * To assess saturation and vital signs through out the procedure. * To assess requirement of buscopan.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hyderabad, Andhra Pradesh, 500082, India
mentioned in complete
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 hour
the pain score measures using Visual Analog scale (VAs - 1 to 10 cm scale )
Time frame: 5 minutes
The abdominal girth was measured prior to patient shifted to ERCP table. The immdiately post ERCP the abdominal girth measured. A fixed point is marked at the umblical regiem to maintain the site of abdominal girth.
Asian Institute of Gastroenterology, India
Other
A Double-blind, Randomized, Controlled Trial of Air Insufflation Versus Carbon Dioxide Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP).
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05155475
Bilio-pancreatic Tumor, Hyperbilirubinemia
Lyon, France
View Trial DetailsNCT05928286
Biliary Tract Diseases, Cholelithiasis
Barnaul, Russia
View Trial DetailsNCT03510754
Digestive System Diseases, Digestive System Neoplasms
View Trial DetailsNCT01191814
Digestive System Diseases, Digestive System Neoplasms
Orlando, Florida, United States
View Trial Details